携带JAK2V617F的血管微环境促进骨髓增殖性肿瘤的克隆性扩增
研究探讨携带JAK2V617F的血管微环境对骨髓增殖性肿瘤中造血干/祖细胞扩增的作用。发现携带JAK2V617F的内皮细胞优先支持JAK2V617F造血干/祖细胞扩增而非野生型细胞,可能与移植后供者细胞植入不良和疾病复发相关;CXCL12和SCF表达上调,TPO/MPL信号通路关键。
要点
- 携带JAK2V617F的血管微环境优先促进JAK2V617F造血干/祖细胞扩增。
- JAK2V617F内皮细胞中CXCL12和SCF表达上调。
- TPO/MPL信号通路对血管微环境功能改变至关重要。
核心结论
- 携带JAK2V617F的血管微环境优先促进JAK2V617F造血干/祖细胞扩增,可能贡献于移植后供者细胞植入不良和疾病复发。
研究设计与样本
- 实验研究,探讨携带JAK2V617F的血管微环境对造血干/祖细胞扩增的作用。
主要发现
- 携带JAK2V617F的血管微环境优先促进JAK2V617F造血干/祖细胞扩增而非JAK2野生型造血干/祖细胞。
- JAK2V617F内皮细胞中CXCL12和SCF表达较野生型内皮细胞上调。
- TPO/MPL信号通路对血管微环境功能改变至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial cells (ECs) are an essential component of the hematopoietic niche, and they have been shown to express the JAK2V617F mutation in patients with MPNs. We show that the JAK2V617F-bearing vascular niche promotes the expansion of the JAK2V617F HSPCs in preference to JAK2WT HSPCs, potentially contributing to poor donor cell engraftment and disease relapse following stem cell transplantation. The expression of Chemokine (C-X-C motif) ligand 12 (CXCL12) and stem cell factor (SCF) were upregulated in JAK2V617F-bearing ECs compared to wild-type ECs, potentially accounting for this observation. We further identify that the thrombopoietin (TPO)/MPL signaling pathway is critical for the altered vascular niche function. A better understanding of how the vascular niche contributes to HSPC expansion and MPN development is essential for the design of more effective therapeutic strategies for patients with MPNs.
引用
- Zhan H, Lin CHS, Segal Y, et al. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia. 2017. PMID: 28744010. doi:10.1038/leu.2017.233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。